Silencing of Kynu reduces the production of 3-HAA and further limits the production of matrix metallopeptidase-2 (MMP2) in SMCs, resulting in reduced AAA formation in Apoe-/- mice (37). This evidence concerns the gene MMP2 and triple-A syndrome.